The efficacy and favorable safety profile of anti-tumor necrosis factor (TNF) agents in the treatment of psoriasis and psoriatic arthritis (PsA) are supported by several randomized controlled studies and meta-analyses. However, some concerns on the long-term safety of these drugs still exist, as these studies generally included small patient numbers and were performed in selected patient populations.

Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis

GIROLOMONI, Giampiero;
2012-01-01

Abstract

The efficacy and favorable safety profile of anti-tumor necrosis factor (TNF) agents in the treatment of psoriasis and psoriatic arthritis (PsA) are supported by several randomized controlled studies and meta-analyses. However, some concerns on the long-term safety of these drugs still exist, as these studies generally included small patient numbers and were performed in selected patient populations.
2012
Adalimumab; Antibodies, Monoclonal; Arthritis, Psoriatic; Etanercept; Humans; Incidence; Infection; Infliximab; Lymphoma; Randomized Controlled Trials as Topic; Time Factors; Tumor Necrosis Factor-alpha; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Immunoglobulin G; Immunosuppressive Agents; Receptors, Tumor Necrosis Factor
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/933403
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 40
social impact